BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Pick Your #1 game to observe - 2Instructions to Guarantee Kids Foster Solid Dental Propensities
- 3Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- 4Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- 5The most effective method to Go with Informed Choices on Vehicle Leases
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Fundamental Home Machines: An Easy to understand Determination Guide
- Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- Key Training: Picking a Significant for Monetary Achievement
- Very good quality Greens All over The Planet
- 'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
- Make your choice for the sweet that transports you to its nation of beginning!
- Before trips to Mars, we need better protection from cosmic rays
- Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’
